Senior Director, Pricing and Market Access, Europe

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers.  The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

The Senior Director, European Pricing & Market Access serves as the regional pricing leader and European pricing voice for Revolution Medicines. This incumbent will be a senior member of the European Market Access Leadership Team and acts as the dedicated European pricing strategist, providing rapid-response pricing scenario capability at product, indication, and portfolio level to support negotiations, pricing governance, and enterprise strategic planning.

The incumbent is accountable for maximizing European value realization while safeguarding long-term global price integrity across the RevMed portfolio. Operating at the intersection of regional execution and global pricing governance, this leader ensures European market dynamics, international reference pricing (IRP) implications, and health technology assessment (HTA) requirements are fully integrated into global pricing architecture and decision-making.

The Senior Director partners closely with Country Senior Directors, Market Access, as well as HEOR, Commercial, Regulatory, Finance, and Global Pricing colleagues, serving as the primary European interface to Global Pricing on all matters related to European pricing strategy. They will be based in Switzerland.

Key responsibilities:

• Deliver rapid European pricing scenario analyses to support pricing governance decisions, payer negotiations, and competitive response, with accountability for analytical rigor, strategic relevance, and executive decision-readiness.

• Own and maintain the European IRP simulation model, tracking basket compositions, referencing rules, revision timing, and exposure across 25+ markets.

• Develop European price corridor recommendations, floor prices, and launch sequencing strategies based on IRP dynamics, HTA timelines, and competitive context.

• Quantify the European revenue impact of proposed global pricing decisions and proactively shape recommendations to optimize regional and global value outcomes.

• Model pricing implications of indication expansions, including MFN/IRP effects on base business and cross-indication value trade-offs.

• Analyze portfolio pricing interdependencies and positioning implications across European markets.

• Balance long-term franchise value against individual product optimization, acting as a steward of portfolio-level value across current and future indications.

• Coordinate with Country Senior Directors, Market Access to provide pricing scenarios supporting live payer negotiations and guide strategic positioning during critical negotiation inflection points.

• Translate country-level pricing intelligence into European and global strategic insights.

• Support country teams with alternative pricing corridor scenarios when negotiations reach impasse.

• Provide leadership, mentorship, and strategic guidance to country and regional pricing colleagues, fostering consistent pricing excellence across European markets.

• Represent the European pricing perspective in global pricing governance forums and committees, serving as the accountable regional leader for European pricing inputs into enterprise decision-making.

• Partner with the Executive Director, Global Pricing on pricing methodology, tools, and governance frameworks.

• Provide European input into global price architecture, launch sequencing, and portfolio pricing decisions.

• Represent European Pricing & Market Access in relevant enterprise governance, portfolio, and risk management forums.

• Own and oversee the operational maintenance of the European pricing database as the single source of truth for list and net prices, including governance, audit trails, and documentation of price changes in alignment with global pricing standards and financial controls.

• Monitor competitor pricing moves, reimbursement decisions, and tender outcomes across European markets.

• Track European pricing policy changes, reforms, and implications of EU Joint Clinical Assessment (JCA) implementation.

• Maintain expert-level knowledge of IRP/MFN mechanics and HTA-driven pricing dynamics across key European markets.

• Translate external pricing and policy developments into forward-looking strategic implications for RevMed’s European and global pricing strategy.

Required Skills, Experience and Education:

• Bachelor’s degree required; advanced degree (MBA, MSc, PhD, PharmD) in health economics, finance, life sciences, or related field preferred.

• 12–15+ years of progressive experience in pharmaceutical or biotech pricing, market access, or health economics, including leadership across multiple European markets within a complex matrix organization.

• Deep expertise in European pricing and reimbursement environments, including MFN/IRP mechanics across major markets.

• Demonstrated experience with European HTA processes (e.g., NICE, G-BA, HAS, AIFA) and their pricing implications.

• Advanced analytical and financial modeling capabilities; experience with pricing intelligence platforms (e.g., IQVIA Pricentric, GlobalData).

• Proven ability to partner effectively with Finance to translate complex pricing agreements and commercial terms into accurate financial treatment, including oversight of gross-to-net revenue adjustments.

• Strong executive presence with demonstrated ability to influence senior and executive-level stakeholders.

• Experience operating in a fast-paced, entrepreneurial biotech environment.

• Oncology, rare disease, or specialty therapeutics experience preferred.

Preferred Skills:

• Experience building or scaling pricing capabilities in a pre-commercial or early-commercial biotech organization.

• Familiarity with EU Joint Clinical Assessment (JCA) regulation and Most Favoured Nation (MFN) and their impact on pricing strategy.

• Multilingual capability (German, French, or other European languages advantageous).

Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact privacy@revmed.com. #LI-Remote #LI-LO1